Latest Institutional Placement News

Page 9 of 64
Percheron Therapeutics has raised $2.3 million through an institutional placement to fully fund its upcoming acute myeloid leukemia clinical trial led by Vanderbilt Health.
Ada Torres
Ada Torres
1 Sept 2026
Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.
Ada Torres
Ada Torres
31 Aug 2026
NOVONIX Limited posted a $24.6 million half-year loss while delivering a critical synthetic graphite sample to Panasonic and reaffirming a 2027 production start. The company raised $21.7 million to fund its North American battery materials expansion amid ongoing U.S. trade and policy developments.
Maxwell Dee
Maxwell Dee
31 Aug 2026
L1 Gold Fund Limited (ASX:LGF) has launched a retail entitlement offer aiming to raise up to $261.7 million by issuing one new share for every three held, priced at $2.25 each. This follows a $254.9 million institutional placement and entitlement offer completed earlier in August.
Victor Sage
Victor Sage
31 Aug 2026
CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.
Ada Torres
Ada Torres
31 Aug 2026
Vection Technologies (ASX:VR1) achieved a major earnings inflection in FY26 with adjusted EBITDA soaring 596% to $3.8 million and generating positive operating cash flow for the first time, underpinned by dual commercial platforms scaling rapidly.
Sophie Babbage
Sophie Babbage
31 Aug 2026
BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.
Sophie Babbage
Sophie Babbage
31 Aug 2026
Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.
Ada Torres
Ada Torres
28 Aug 2026
Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.
Ada Torres
Ada Torres
27 Aug 2026
Aeris Resources delivered a standout FY26 with revenues up 22% and profit after tax surging 295%, buoyed by operational gains and a strategic acquisition of Peel Mining.
Maxwell Dee
Maxwell Dee
27 Aug 2026
Alliance Aviation Services has completed the institutional portion of its $40 million equity raise, securing $33 million to support its turnaround and debt reduction efforts. The retail entitlement offer opens in early September.
Victor Sage
Victor Sage
27 Aug 2026
Credit Clear Limited posted a 28% rise in FY26 revenue to $60 million, boosted by UK acquisitions and organic growth, while defending legal action by the ACCC.
Claire Turing
Claire Turing
27 Aug 2026

Browse the archive

Full archive